Publication:
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries

Simple item page
dc.contributor.authorGarcía-Betancur, Juan Carlos
dc.contributor.authorCadena, Elsa de la
dc.contributor.authorMojica, María F.
dc.contributor.authorHernández-Gómez, Cristhian
dc.contributor.authorCorrea, Adriana
dc.contributor.authorRadice, Marcela A.
dc.contributor.authorCastañeda Méndez
dc.contributor.authorVillalon, Jaime
dc.contributor.authorGales, Ana C.
dc.contributor.authorMunita, José
dc.contributor.authorVillegas, María Virginia
dc.date.accessioned2023-07-07T15:53:48Z
dc.date.available2023-07-07T15:53:48Z
dc.date.issued2022
dc.description.abstractBackground: Ceftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against Pseudomonas aeruginosa and tazobactam, a known β-lactamase inhibitor. The aim of this study was to evaluate the activity of C/T against clinical isolates of P. aeruginosa and Enterobacterales collected from five Latin American countries between 2016 and 2017, before its clinical use in Latin America, and to compare it with the activity of other available broad-spectrum antimicrobial agents. Methods: a total of 2760 clinical isolates (508 P. aeruginosa and 2252 Enterobacterales) were consecutively collected from 20 hospitals and susceptibility to C/T and comparator agents was tested and interpreted following the current guidelines. Results: according to the CLSI breakpoints, 68.1% (346/508) of P. aeruginosa and 83.9% (1889/2252) of Enterobacterales isolates were susceptible to C/T. Overall, C/T demonstrated higher in vitro activity than currently available cephalosporins, piperacillin/tazobactam and carbapenems when tested against P. aeruginosa, and its performance in vitro was comparable to fosfomycin. When tested against Enterobacterales, it showed higher activity than cephalosporins and piperacillin/tazobactam, and similar activity to ertapenem. Conclusions: these results show that C/T is an active β-lactam agent against clinical isolates of P. aeruginosa and Enterobacterales
dc.description.versionVersión publicada
dc.identifier.citationGarcía-Betancur JC, De La Cadena E, Mojica MF, Hernández-Gómez C, Correa A, Radice MA, Castañeda-Méndez P, Jaime-Villalon DA, Gales AC, Munita JM, et al. Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries. Antibiotics. 2022; 11(8):1101. https://doi.org/10.3390/antibiotics11081101
dc.identifier.doihttps://doi.org/10.3390/antibiotics11081101
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7653
dc.language.isoen
dc.subjectCeftolozane/tazobactam
dc.subjectPseudomonas aeruginosa
dc.subjectEnterobacterales
dc.subjectAntimicrobial resistance
dc.subjectLatin America
dc.titleComparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceAntibiotics
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
antibiotics-11-01101-v2.pdf
Size:
1.01 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services